· Insider activity · ABBV

AbbVie Inc (ABBV) director acquisition adds insider angle to a strong tape

The disclosure gives investors a governance marker as the drugmaker trades with heavier turnover and firm relative performance.

AbbVie pharmaceutical manufacturing equipment with market data screens in a healthcare finance setting.

AbbVie Inc (ABBV) disclosed insider activity dated May 8, with director Jennifer L. Davis acquiring 1,118 shares of common stock at a reported transaction price of $0.00. The stock last closed at $253.35.

Weekly market data show a 17.0% one-week return and a 16.4% four-week return, with latest volume at 2.61 times the 13-week average. Market Dynamics is positive confirmation at 0.79 and Relative Strength is 9.3, though the trend signal remains inactive.